Cleared Traditional

K915130 - MAT MEMBRANE AUTOTRANSFUSION SYSTEM

K915130 is an FDA 510(k) clearance for MAT MEMBRANE AUTOTRANSFUSION SYSTEM, manufactured by Estracorporeal, Inc.. The device is a Class 2 Anesthesiology device with product code CAC cleared through the Traditional 510(k) pathway after a 467-day FDA review.

K915130 · Estracorporeal, Inc. · Anesthesiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 1993
Decision
467d
Days
Class 2
Risk

K915130 is an FDA 510(k) clearance for the MAT MEMBRANE AUTOTRANSFUSION SYSTEM. Classified as Apparatus, Autotransfusion (product code CAC), Class II - Special Controls.

Submitted by Estracorporeal, Inc. (Salt Lake City, US). The FDA issued a Cleared decision on February 22, 1993 after a review of 467 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Anesthesiology FDA review panel, regulated under 21 CFR 868.5830 - the FDA anesthesiology and respiratory device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Anesthesiology submissions.

View all Estracorporeal, Inc. devices

FDA 510(k) Submission Details - K915130

510(k) Number K915130 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 13, 1991
Decision Date February 22, 1993
Days to Decision 467 days
Submission Type Traditional
Review Panel Anesthesiology (AN)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
327d slower than avg
Panel avg: 140d · This submission: 467d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

CAC Device Classification - Class 2, Special Controls

Product Code CAC Apparatus, Autotransfusion
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 868.5830
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Anesthesiology devices follow this clearance model.

Regulatory Peers - CAC Apparatus, Autotransfusion

All 176
Devices cleared under the same product code (CAC) and FDA review panel - the closest regulatory comparables to K915130.
BIOSURGE(TM) SYNCHRONOUS AUTOTRANS PROCEDURE KIT
K931106 · Deknatel, Inc. · Oct 1993
IMPRAFLO(TM) POST OPERATIVE/DRAIN/REINFUS KIT/CANI
K925827 · Impra, Inc. · Jul 1993
AUTOTRANSFUSION SUCTION SET
K920618 · Lifestream Int'L, Inc. · Mar 1993
AUTOVAC 7900 SERIES
K924894 · Boehringer Laboratories · Feb 1993
DAVOL ORTHOPAEDIC AUTOTRANSFUSION SYSTEM
K914119 · Davol, Inc. · Dec 1992
AUTOLOGOUS BLOOD COLLECTION SET
K923016 · Advanced Haemotechnologies · Nov 1992